Pharmaceuticals
YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market
* Strategic Move Positions YD Bio Limited for Accelerated Innovation and Market Expansion * Trading of common stock and warrants of the new public company, YD Bio Limited, is expected to commence on the Nasdaq Global Market onAugust 29, 2025, under the ticker symbols "YDES" and "YDESW" NEW YO...
2025-08-29 19:30
2782
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
* 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies * Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning in chil...
2025-08-29 14:00
2154
Everest Medicines Announces Interim Results for First Half of 2025
SHANGHAI, Aug. 29, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2025 a...
2025-08-29 07:52
2670
Celaid Therapeutics have executed a collaborative research agreement with AGC on Expansion and Functional Evaluation of iPSC-HSPCs
TOKYO, Aug. 28, 2025 /PRNewswire/ -- Celaid Therapeutics Inc. ("Celaid") have executed a collaborative research agreement with AGC Inc. ("AGC") to advance iPS cell-derived hematopoietic stem and progenitor cells (iPSC-HSPCs). The collaboration aims to combine Celaid's proprietary platform of hema...
2025-08-28 22:00
1137
D3 Bio, Inc. Announces FDA Breakthrough Therapy Designation and Orphan Drug Designation for D3S-001 for the Treatment of Patients with KRAS G12C-Mutated Cancers
* Breakthrough Therapy Designation was granted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have had prior treatment with platinum-based chemotherapy and anti-PD-(L)1 antibody but have not been previously treate...
2025-08-28 21:00
3201
LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee
BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious d...
2025-08-28 20:00
2364
ACROBiosystems and DAAN Biotherapeutics Sign Strategic MOU for the Development of Precision Immuno-Oncology Therapeutics
SEOUL, South Korea, Aug. 28, 2025 /PRNewswire/ -- ACROBiosystems, a global biotechnology company dedicated to accelerating the drug development process through innovative tools and solutions, announced that it has entered into a strategic Memorandum of Understanding (MOU) with DAAN Biotherapeutic...
2025-08-28 09:54
1572
AIM Vaccine Forecasts Surge in Stock Performance: Innovations Reinforce Leadership in Vaccine Sector
HONG KONG, Aug. 28, 2025 /PRNewswire/ -- AIM Vaccine (06660.HK), a leading domestic vaccine company, announced today the release of its 2025 interim report, showcasing robust revenue growth. With major products entering the market phase, R&D costs are decreasing, and operational expenditures are ...
2025-08-28 07:45
1351
Ascletis Announces Favorable and Differentiated Pharmacokinetic Profile of ASC30 Oral Once-Daily Tablet in Its U.S. Phase Ib Multiple Ascending Dose Study
- ASC30 oral once-daily tablet demonstrated approximately 2.3-fold to 3.3-fold greater drug exposure than orforglipron in a cross-trial comparison. - Higher drug exposure and favorable tolerability profile positions ASC30 oral once-daily tablet favorably compared to orforglipron...
2025-08-28 07:45
1219
Fangzhou Posts Strong 1H Revenue and Profit as Physician Network and User Base Expand
HONG KONG, Aug. 27, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, reported a profitable first half of 2025, supported by an expanding user base, higher operating efficiency, and accelerated deployment of AI across...
2025-08-27 23:09
2259
Harbour BioMed Reports 2025 Interim Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its i...
2025-08-27 22:40
2087
Fosun International: Total Revenue for the First Half of 2025 Reaches RMB87.28 Billion, Industrial Operation Profit Amounts to RMB3.15 Billion
HONG KONG, Aug. 27, 2025 /PRNewswire/ -- On 27 August, Fosun International Limited (HKEX stock code: 00656) announced its interim results for the six months ended30 June 2025. In the first half of 2025, Fosun actively captured macroeconomic trends, maintained a clear strategic focus, and leverag...
2025-08-27 20:40
3412
Innovent Announces 2025 Interim Results and Business Updates
* Robust revenue growth and substantial profit improvement * Continued exceptional executions under a clear roadmap of dual-driven growth and global innovation SAN FRANCISCO and SUZHOU, China, Aug. 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class bioph...
2025-08-27 18:08
2892
Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum
CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress. Financially, the company achieved record revenue, driven by the strong performance of its core produ...
2025-08-27 14:02
1031
Fosun Pharma Announces 2025 Interim Results
Enhancing Innovation Efficiency and Steadily Expanding Globally SHANGHAI, Aug. 26, 2025 /PRNewswire/ -- On August 26, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company, announced ...
2025-08-26 20:42
2110
Brightonix Imaging's High-Performance 'PHAROS' PET Receives FDA Clearance
SEOUL, South Korea, Aug. 26, 2025 /PRNewswire/ -- Brightonix Imaging, a global leader in cutting-edge medical imaging technology, is proud to announce that its flagship product, thePHAROS PET Scanner, has received FDA clearance for commercial distribution inthe United States. This milestone marks...
2025-08-26 19:00
1346
Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment
* Abbott's denosumab biosimilar is the first approved in Thailand, making advanced therapy for osteoporosis and cancer-related bone loss more affordable for millions of Thais * This approval builds on Abbott's biosimilar portfolio in Asia Pacific, following recent launches inMalaysia and Indi...
2025-08-26 14:29
1687
Basecare Medical (02170.HK) Gems Culture Medium Receives First Approval from NMPA, Advancing the Localization of Assisted Reproductive Fluids
SUZHOU, China, Aug. 26, 2025 /PRNewswire/ -- Recently, Suzhou Basecare Medical Co., Ltd. achieved a major breakthrough—its globally leading Gems culture medium (embryo handling solution VitBase) has officially received registration approval from the National Medical Products Administration (NMPA)...
2025-08-26 11:47
1800
Neopharma Technologies and Orient Gene Partner to Digitize Healgen® Drug Test Portfolio Globally with NEOVAULT®
Partnership delivers tamper-evident, high-integrity testing data aligned with U.S. Drug Policy Priorities WASHINGTON, Aug. 26, 2025 /PRNewswire/ -- Neopharma Technologies Limited ("Neopharma") today announced it hasentered into a global software licensing and collaboration agreement with Zhejian...
2025-08-26 02:10
1495
Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach
SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2025 interim results. In the first half of 2025, Henlius' revenue reached about RMB2.8195 billion, representing an increase of 2.7% YoY. The gross profit of RMB2.1992 billion, up by 10.5% YoY, with a net profit reached RMB390....
2025-08-25 21:18
2840
Week's Top Stories
Most Reposted
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
Synvo AI and Sobat Bisnis Group (SBG) Forge Strategic Partnership to Bring Secure, Context-Aware Enterprise AI to Indonesia and Southeast Asia
[Picked up by 290 media titles]
2025-12-16 08:00
Colebrook Bosson Saunders Chooses India for First Executive Dialogue Exploring Future of Workspaces and Technology
[Picked up by 287 media titles]
2025-12-16 14:26
Who Are China's Top 100 Most International Privately-Owned Enterprises?
[Picked up by 268 media titles]
2025-12-15 16:55
AbbVie Ranked #15 in the Inaugural Fortune 100 Best Companies to Work For Southeast Asia 2025 List
[Picked up by 258 media titles]
2025-12-15 09:00
